Grail is a high-volatility, FDA-dependent pure-play on making multi-cancer blood screening a reimbursed standard of care—massive upside if approved, severe downside if delayed.
Overview
Grail (GRAL) is a pure-play leader in multi-cancer early detection (MCED) via liquid biopsy, commercializing the Galleri blood test that can detect signals for 50+ cancers and predict cancer signal origin using cfDNA methylation patterns, next-gen sequencing, and machine learning. Revenue is primarily from Galleri screening (FY2025: 185k+ tests, +35% YoY; U.S. Galleri revenue $136.8M, +26%), with a smaller development-services segment with biopharma partners (Amgen/AZ/BMS) that declined in 2025 ($8.6M vs $17.0M). FY2025 revenue was $147.2M (+17%), with a GAAP net loss of $408.4M driven in part by large non-cash amortization/impairments; adjusted EBITDA improved materially. With $904.4M cash, management expects runway into 2030, spanning the pivotal shift from LDT/self-pay to FDA-approved, reimbursed adoption.